Ani Pharmaceuticals (ANIP) Payables: 2009-2025
Historic Payables for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $69.8 million.
- Ani Pharmaceuticals' Payables rose 14.62% to $69.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $223.1 million, marking a year-over-year increase of 14.00%. This contributed to the annual value of $45.7 million for FY2024, which is 24.46% up from last year.
- Ani Pharmaceuticals' Payables amounted to $69.8 million in Q3 2025, which was up 27.90% from $54.6 million recorded in Q2 2025.
- In the past 5 years, Ani Pharmaceuticals' Payables registered a high of $69.8 million during Q3 2025, and its lowest value of $11.5 million during Q3 2021.
- Its 3-year average for Payables is $46.7 million, with a median of $48.7 million in 2024.
- In the last 5 years, Ani Pharmaceuticals' Payables declined by 14.47% in 2021 and then soared by 113.00% in 2022.
- Over the past 5 years, Ani Pharmaceuticals' Payables (Quarterly) stood at $23.0 million in 2021, then rose by 27.60% to $29.3 million in 2022, then grew by 25.18% to $36.7 million in 2023, then grew by 24.46% to $45.7 million in 2024, then climbed by 14.62% to $69.8 million in 2025.
- Its Payables was $69.8 million in Q3 2025, compared to $54.6 million in Q2 2025 and $53.1 million in Q1 2025.